Section 01

Endogenous GLP-1

Biosynthesis, secretion, and physiological half-life

Glucagon-like peptide-1 (GLP-1) is an incretin hormone — a gut-derived peptide that augments glucose-stimulated insulin secretion. It was first isolated from intestinal extracts in the 1980s following the cloning of the proglucagon gene, and is now understood to be one of two principal incretins alongside glucose-dependent insulinotropic polypeptide (GIP).

💡
Clinical Pearl — The Incretin Effect
Oral glucose elicits 2–3× greater insulin secretion than an equivalent intravenous glucose infusion — a phenomenon called the incretin effect. This accounts for approximately 50–70% of postprandial insulin release in healthy individuals. In type 2 diabetes, the incretin effect is markedly diminished but not absent — a key pharmacological target.
Biosynthesis — Proglucagon Processing

The human GCG gene is located at 2q24.2. Tissue-specific processing of its precursor determines the peptides released. In intestinal L-cells, prohormone convertase 1/3 (PC1/3) generates active GLP-1 and other products. NCBI GCG gene record.

Proglucagon processing in two tissues
Pancreatic alpha cell and intestinal L-cell with tissue cutaways: PC2 favours glucagon production, while PC1/3 produces intestinal GLP-1, GLP-2 and oxyntomodulin.
Figure 1. Tissue-specific processing: PC2 predominantly generates glucagon in pancreatic alpha cells; intestinal PC1/3 generates GLP-1 and other proglucagon-derived peptides. The products shown are selected examples, not a complete cleavage map. L-cell hormone release is basolateral into the circulation; apical particles represent luminal contents. Human PC1-deficiency study. Original AI-assisted educational schematic; structures and molecules are not to scale.
Secretion — L-Cell Physiology

Enteroendocrine L-cells occur throughout the intestine, with greater density distally. Proximal L-cells can respond directly to nutrients and contribute to the early post-meal GLP-1 rise; an early response should not be attributed solely to a neural reflex. Human intestinal glucose-sensing study.

⚠
DPP-4 Degradation — The Pharmacological Challenge
Native GLP-1 has a plasma half-life of <2 minutes due to rapid cleavage by dipeptidyl peptidase-4 (DPP-4), which removes the N-terminal His-Ala dipeptide to yield the inactive metabolite GLP-1 (9-36 amide). This near-complete first-pass degradation was the principal barrier to therapeutic use — overcome in GLP-1 RAs by structural modification to resist DPP-4 cleavage.
Section 02

Receptor Structure & Distribution

Class B GPCR — tissue-specific expression pattern

The GLP-1 receptor (GLP-1R) is a class B (secretin family) G-protein coupled receptor encoded by the GLP1R gene on chromosome 6p21. It consists of 463 amino acids with a large extracellular N-terminal domain, seven transmembrane helices, and three intracellular loops — the structural basis for Gs-protein coupling and downstream cAMP signalling.

GLP-1 signalling and organ effects
Anatomical brain, stomach and pancreatic beta-cell pathways shown separately from heart, kidney and liver outcomes; organ benefits do not demonstrate receptor expression in every cell.
Figure 2. Physiological pathways and downstream organ effects. Clinical benefit does not establish direct receptor expression. Validated localisation is cell-specific; human hepatocyte and renal proximal-tubule expression should not be assumed from treatment outcomes. Benefit depends on the medicine, population and endpoint. Validated receptor localisation; human liver localisation study. Original AI-assisted educational schematic; structures and molecules are not to scale.
Section 03

Intracellular Signalling Cascade

cAMP–PKA axis, EPAC2, and ion channel modulation

GLP-1R activation initiates a canonical Gs-protein coupled signalling pathway, with secondary signalling through EPAC2 (exchange protein directly activated by cAMP). Together, these pathways converge on calcium-dependent insulin exocytosis and transcriptional regulation of beta-cell gene expression.

1
GLP-1 Binding to Extracellular Domain
GLP-1 (or a GLP-1 RA) binds the large N-terminal extracellular domain of GLP-1R. The peptide adopts an α-helical conformation, with the C-terminus engaging the extracellular domain and the N-terminus inserting into the transmembrane bundle to stabilise the active receptor conformation. Binding affinity (EC₅₀) for native GLP-1 is approximately 1–5 nmol/L.
Receptor activation
2
Gs-Protein Coupling → Adenylyl Cyclase Activation
Receptor conformational change activates the coupled heterotrimeric Gs-protein. The Gαs subunit dissociates and directly stimulates adenylyl cyclase (AC), catalysing the conversion of ATP to cyclic AMP (cAMP). Beta-cell cAMP rises 3–10-fold above basal within seconds of GLP-1 exposure.
Gs coupling
3
cAMP → PKA Activation
Elevated cAMP activates protein kinase A (PKA). Its targets influence beta-cell electrical activity, calcium handling and exocytotic proteins, amplifying glucose-stimulated insulin release alongside the Epac2 pathway.
PKA axis
4
EPAC2 Pathway — PKA-Independent cAMP Signalling
cAMP also directly activates EPAC2 (Rap GEF), a guanine nucleotide exchange factor that activates Rap1 GTPase. EPAC2 signalling potentiates insulin secretion through: (i) sensitisation of the ryanodine receptor → enhanced Ca²⁺ release from endoplasmic reticulum; (ii) activation of phospholipase C-ε → IP₃/diacylglycerol production. EPAC2 is critical for the first-phase insulin secretion restoration seen with GLP-1 RAs.
EPAC2 axis
5
KATP Channel Closure → Membrane Depolarisation
Glucose-derived ATP reduces KATP-channel opening and K⁺ efflux, producing membrane depolarisation. Voltage-gated calcium channels then allow Ca²⁺ entry. cAMP signalling modulates this process and the downstream exocytotic machinery.
Ion channel modulation
6
Ca²⁺ Influx → Insulin Vesicle Exocytosis
Cytosolic Ca²⁺ elevation (from both VDCC influx and ER release) triggers SNARE-complex assembly (SNAP-25, syntaxin-1, VAMP-2) and fusion of insulin-containing secretory granules with the plasma membrane. GLP-1 signalling lowers the Ca²⁺ threshold for exocytosis and recruits reserve pool granules — thereby restoring both first-phase (rapid, 0–10 min) and second-phase (sustained, 10–120 min) insulin secretion, which are characteristically blunted in type 2 diabetes.
Insulin exocytosis
7
Nuclear Signalling — Beta-Cell Gene Transcription
PKA-activated CREB (cAMP response element-binding protein) translocates to the nucleus and upregulates transcription of PDX-1, NeuroD1, and Nkx6.1 — master regulators of beta-cell identity. This promotes insulin gene expression, beta-cell differentiation, and in preclinical models, beta-cell mass expansion through increased proliferation and reduced apoptosis (via PI3K/Akt pathway). Clinical translation of beta-cell preservation in humans remains under investigation.
Transcriptional regulation
⚗
Mechanism Note — Receptor Trafficking
Sustained GLP-1R agonism causes receptor internalisation via β-arrestin recruitment, reducing surface receptor density (homologous desensitisation). Biased agonism — favouring Gs over β-arrestin coupling — is an active area of drug development, aiming to preserve signalling potency during continuous exposure. Current licensed agents differ in their β-arrestin recruitment profiles, which may partly explain differences in durability of glycaemic effect.
Section 04

Pancreatic Effects

Beta-cell, alpha-cell, and delta-cell physiology

The pancreas is the primary pharmacological target of GLP-1 RAs. Effects span insulin secretion augmentation, glucagon suppression, and potential modification of islet cell mass — each with distinct mechanistic bases and clinical relevance.

Beta-Cell Effects — Insulin Secretion

GLP-1 RAs restore the biphasic insulin secretion pattern characteristically lost in T2DM. First-phase secretion (the acute spike within 10 minutes of glucose exposure) depends on readily-releasable granule pools; GLP-1 signalling through EPAC2 recruits these granules and lowers the Ca²⁺ trigger threshold. Second-phase secretion draws on reserve pool granules mobilised through both PKA and PI3K pathways.

HbA1c reduction (mono)
−1.0–1.8%
SUSTAIN programme · semaglutide
Fasting glucose reduction
−1.6mmol/L
vs placebo · SUSTAIN-1
Postprandial glucose (AUC)
−35%
Combined gastric + insulin effect
First-phase insulin response
+2.4×
vs baseline in T2DM subjects
Alpha-Cell Effects — Glucagon Suppression

GLP-1 reduces inappropriate glucagon secretion during hyperglycaemia. Direct alpha-cell receptor signalling and indirect islet mechanisms must be distinguished: receptor detection varies with species and method, and insulin/somatostatin-mediated paracrine inhibition also matters. Human alpha-cell paracrine study; receptor-labelling study.

📊
Evidence — Glucagon Suppression
Semaglutide reduces glucagon during hyperglycaemia. In a hypoglycaemic clamp study, counter-regulatory glucagon responses were retained. This is distinct from claiming direct receptor action in every alpha cell. UK Ozempic SmPC, section 5.1.
Delta-Cell & Paracrine Effects

Islet cell-to-cell signalling contributes to glucagon regulation. Delta-cell somatostatin and beta-cell insulin provide paracrine signals; the relative contribution of direct and indirect GLP-1 effects remains context-dependent. Experimental observations should not be presented as uniform receptor expression in every human alpha cell.

Section 05

Extrapancreatic Effects

CNS, cardiovascular, renal, hepatic, and gastrointestinal

SystemEstablished function or outcomeInterpretation
Brain and neural pathwaysAppetite, food intake and nausea signallingDistributed hypothalamic, brainstem and neural circuits; not a single appetite centre.
Gastrointestinal tractSlower gastric emptyingMagnitude varies with agent and exposure; consider residual gastric contents around anaesthesia.
Cardiovascular systemCardiovascular outcome benefits with specific agentsClinical trial outcomes do not prove direct receptor action in all cardiomyocytes.
KidneyKidney outcome benefits in defined trial populationsRenal vascular localisation differs from a claim of uniform proximal-tubule receptor expression.
LiverReduced liver fat and improved MASH outcomes with specific treatmentsIndirect metabolic pathways matter; direct human hepatocyte GLP-1R expression is not established by clinical benefit.

Sources: receptor-localisation study; human liver study; agent-specific cardiovascular, kidney and MASH trials.

💡
Clinical Pearl — CNS Mechanism of Weight Loss
Hypothalamic GLP-1R activation in the arcuate nucleus inhibits orexigenic NPY/AgRP neurons and activates anorexigenic POMC/CART neurons, reducing appetite drive and caloric intake. Crucially, GLP-1 RAs appear to reduce food reward salience — blunting hedonic eating — via mesolimbic dopamine pathway modulation, explaining reductions in binge eating and food cravings observed clinically before significant weight loss occurs.
Section 06

Glucose-Dependent Insulinotropism

The mechanistic basis of hypoglycaemia safety

GLP-1 receptor agonists have a low intrinsic risk of hypoglycaemia because they predominantly amplify glucose-stimulated insulin secretion. Low risk is not zero risk, particularly when treatment is combined with insulin or sulfonylureas.

GLP-1 amplifies glucose-stimulated insulin secretion. Its insulinotropic effect diminishes as glucose falls; there is no single universal on/off glucose threshold.

Mechanistic Basis — KATP Channel Requirement

Glucose metabolism raises the ATP/ADP ratio, reducing KATP-channel activity and promoting depolarisation and calcium entry. GLP-1 signalling amplifies this secretory response through PKA and Epac2, including effects on ion channels and insulin-granule mobilisation. It is not adequately explained by one obligatory phosphorylation step. Experimental amplification study.

Glucose triggering and GLP-1 amplification
Beta-cell cutaway: glucose metabolism raises ATP/ADP, closes KATP channels and triggers calcium entry; GLP-1R signalling through cAMP, PKA and Epac2 amplifies insulin-granule exocytosis.
Figure 3. Glucose metabolism initiates electrical and calcium signals; GLP-1R–Gs–adenylyl cyclase–cAMP signalling through PKA and Epac2 amplifies secretion. The response varies continuously with glucose rather than switching at fixed thresholds. Intrinsic hypoglycaemia risk is low, and increases with insulin or sulfonylureas. Experimental PKA/Epac amplification study; UK semaglutide product information. Original AI-assisted educational schematic; structures and molecules are not to scale.
⚠
Caution — Combination with Sulphonylureas or Insulin
When adding a GLP-1 medicine to insulin or a sulfonylurea, consider reducing the co-therapy dose and increase glucose monitoring according to the individual patient and current product information. Do not apply an automatic universal 50% reduction. UK semaglutide SmPC, sections 4.2 and 4.4.
Section 07

Drug-Specific Pharmacology

Structural basis of receptor activity and extended half-life

All licensed GLP-1 RAs share the core pharmacological mechanism of GLP-1R agonism but differ fundamentally in their structural basis for DPP-4 resistance, albumin-binding strategy, elimination half-life, and receptor activation kinetics. These differences translate into clinically relevant distinctions in dosing frequency, weight loss potency, and adverse effect profile.

Twice daily
Exenatide
Byetta · Bydureon (XR) · First in class
Origin
Exendin-4 (Gila monster)
GLP-1 Homology
53% sequence identity
Half-life (IR)
~2.4 hours
Half-life (XR)
~2 weeks (PLGA microspheres)
Structural Basis of Activity
Exenatide is a synthetic version of exendin-4, a peptide isolated from the venom of the Gila monster (Heloderma suspectum). It shares 53% sequence homology with human GLP-1 but critically differs at position 2: Gly replaces Ala, conferring resistance to DPP-4 cleavage. The extended-release formulation (Bydureon) encapsulates exenatide in poly(lactic-co-glycolic acid) microspheres for subcutaneous depot release, achieving once-weekly dosing through slow polymer degradation rather than pharmacokinetic modification of the peptide itself.
Once daily
Liraglutide
Victoza (T2DM) · Saxenda (obesity)
GLP-1 Homology
97% sequence identity
Modification
C16 fatty acid chain (Lys26)
Half-life
~13 hours
Albumin binding
>98% (non-covalent)
Structural Basis of Activity
Liraglutide is a GLP-1 analogue with Lys34 replaced by Arg and a C16 fatty-acid side chain attached at Lys26 through a glutamate spacer. Albumin binding and delayed absorption support once-daily administration. The position-34 substitution leaves Lys26 available for selective acylation; it should not be described as the reverse substitution.
Once weekly · Oral available
Semaglutide
Ozempic (SC) · Wegovy (SC obesity) · Rybelsus (oral)
GLP-1 Homology
94% sequence identity
Modification
C18 fatty diacid · mini-PEG linker
Half-life
~7 days (165–184 h)
Albumin affinity
3–4× greater than liraglutide
Structural Basis of Activity
Semaglutide combines Aib at position 8 for DPP-4 resistance, Lys34→Arg and a C18 fatty-diacid side chain attached at Lys26 for albumin binding. Its approximately one-week half-life supports weekly injection. Oral semaglutide uses the absorption enhancer SNAC; formulation-specific instructions and bioavailability differ. UK semaglutide product information.
Once weekly
Dulaglutide
Trulicity · Fc-fusion technology
Structure
GLP-1 × 2 + IgG4 Fc fusion
Molecular weight
~60 kDa (large protein)
Half-life
~5 days (112 hours)
Special property
FcRn recycling → long t½
Structural Basis of Activity
Dulaglutide employs an entirely different strategy — rather than albumin binding, it uses IgG4 Fc fusion. Two modified GLP-1 molecules are linked to the Fc region of IgG4 via a small peptide connector. The large molecular size (~60 kDa) prevents renal filtration, while neonatal Fc receptor (FcRn) recycling — the same mechanism that extends IgG antibody half-lives — rescues dulaglutide from lysosomal degradation, yielding a ~5-day half-life and once-weekly dosing. The Fc region is further modified (Leu234Ala, Leu235Ala) to minimise Fc-effector functions and reduce immunogenicity.
Dual agonist · Once weekly
Tirzepatide
Mounjaro (T2DM) · Zepbound (obesity) · GIP/GLP-1 dual
Mechanism
GIP-R + GLP-1R dual agonism
GIP-R activity
Full agonist (EC₅₀ ~0.05 nM)
GLP-1R activity
Partial agonist (lower potency)
Max weight loss
Up to 22.5% (SURMOUNT-1)
Dual Agonism — A Distinct Mechanism Class
Tirzepatide represents a mechanistic advance beyond GLP-1 RA — it is a dual GIP/GLP-1 receptor co-agonist , acting as a full agonist at the GIPR and a partial agonist (with biased signalling characteristics) at GLP-1R. Its structure is based on the 39-amino-acid sequence of GIP with modifications for GLP-1R co-binding, extended by a C20 fatty diacid chain for albumin binding (approximately 5-day half-life). The complementary mechanisms include: GIP-mediated potentiation of insulin secretion through its own cAMP pathway; GIP's adipocyte-level lipid metabolism modulation (reducing lipotoxicity); and GLP-1R-mediated appetite suppression and gastric emptying delay. The GIPR agonism also appears to paradoxically enhance GLP-1-mediated weight loss — likely through synergistic hypothalamic effects and adipose tissue energy handling — producing substantially greater weight reduction than selective GLP-1R agonism at equivalent tolerability.
Pharmacological Comparison
Property
Liraglutide
Semaglutide SC
Tirzepatide
Dosing
Once daily
Once weekly
Once weekly
t½
~13 h
~7 days
~5 days
HbA1c ↓
~1.1%
LEADER
~1.5–1.8%
SUSTAIN-1
~2.0–2.3%
SURPASS-2
Weight loss
~5–6%
Victoza dose
~10–15%
2.4 mg (Wegovy)
~15–22%
15 mg (SURMOUNT)
CV evidence
LEADER +
SELECT +
SURPASS-CVOT +
Oral form
No
Yes (Rybelsus)
In development
Section 08

Tirzepatide — Dual Agonism

GIP receptor pharmacology and synergistic weight loss

GIP is released predominantly from proximal intestinal K-cells and signals through GIPR. In type 2 diabetes, the insulinotropic response to native GIP is reduced, whereas pharmacological GLP-1 responsiveness is relatively preserved. This does not mean GIPR co-agonism cannot contribute to the clinical effects of tirzepatide. Human incretin comparison.

⚗
Dual agonism — mechanistic hypotheses
Tirzepatide activates both GIPR and GLP-1R. Neural and metabolic contributions are under investigation; clinical superiority to a comparator does not by itself prove pharmacological synergy or identify the responsible receptor pathway. Mechanistic appraisal.
📊
Evidence — SURMOUNT-1 (NEJM 2022)
SURMOUNT-1 enrolled 2,539 adults without diabetes with BMI ≥30, or ≥27 with a weight-related complication. At 72 weeks, treatment-regimen mean weight change was −15.0%, −19.5% and −20.9% with tirzepatide 5/10/15 mg versus −3.1% with placebo. These are within-trial comparisons and do not demonstrate superiority to every other medicine. SURMOUNT-1 primary report.

Key primary sources are linked beside each updated mechanism claim. Clinical outcome comparisons and current prescribing status are covered in the evidence, drug-class and regulatory chapters. Mechanistic hypotheses must be distinguished from demonstrated clinical effects.